Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer

Journal of Thoracic and Cardiovascular Surgery(2020)10.1016/j.jtcvs.2020.11.106Source: DataRank Database

Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer is a research paper published in Journal of Thoracic and Cardiovascular Surgery (2020). On theSindex it has a DataRank of 0. It has been cited 97 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access97 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 14.10)OA: greenTopics (54)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Geoffrey Y. Ku ORCID,Kay See Tan ORCID,Samuel C. Nussenzweig,Abraham J. Wu ORCID,Yelena Y. Janjigian ORCID

Live enrichment

PubMed:33485662 PMC:PMC7889638 OpenAlex:https://openalex.org/W3111138509

NCI NIH HHS

Grant: R01 CA217169

NCI NIH HHS

Grant: R01 CA240472

NCI NIH HHS

Grant: P30 CA008748

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

National Institutes of Health

Grant: 1R01CA240472-01

Targeting SNP BRMS1v2 A273V/A273V to reduce metastases in lung adenocarcinoma

National Institutes of Health

Grant: 5R01CA217169-04

BRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinoma

National Institutes of Health

FWCI

14.10

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

greenLicense: Elsevier Non-Commercial

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7889638

publisherhttps://api.elsevier.com/content/article/PII:S0022522320331925?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0022522320331925?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jtcvs.2020.11.106

Fields of Study

Esophageal Cancer Research and TreatmentCancer Immunotherapy and BiomarkersEosinophilic Esophagitis03 medical and health sciences0302 clinical medicine

MeSH Terms

AdenocarcinomaAgedEsophageal NeoplasmsFeasibility StudiesFemaleHumansImmunotherapyMaleMiddle AgedPatient ReadmissionPostoperative ComplicationsRetrospective StudiesRisk FactorsTime FactorsDatabases, FactualEsophagectomyTreatment OutcomeClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicRisk AssessmentNeoadjuvant TherapyChemoradiotherapy, AdjuvantPatient Safety

Keywords

Esophageal cancerMedicineEsophagectomyChemoradiotherapyImmunotherapyOncologyInternal medicineCancerMaleClinical Trials, Phase I as TopicDatabases, FactualEsophageal NeoplasmsChemoradiotherapy, AdjuvantAdenocarcinomaMiddle AgedPatient ReadmissionRisk AssessmentNeoadjuvant TherapyClinical Trials, Phase II as TopicPostoperative ComplicationsFeasibility StudiesHumansFemalePatient SafetyAgedRetrospective Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being